Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Burkitt Lymphoma 20Leukemia, Biphenotypic, Acute 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 3Leukemia 3Neoplasm, Residual 2Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Down Syndrome 1Blast Crisis 1Bites and Stings 1

Interventions

ponatinib 4Methotrexate 4Cyclophosphamide 4merphos 3fludarabine phosphate 3Whole-Body Irradiation 3Tacrolimus 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Cytarabine 2CT-P10 2Busulfan 2venetoclax 1prednylidene 1pegylated granulocyte colony-stimulating factor 1letermovir 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1blinatumomab 1auricularum 1Vincristine 1Thiotepa 1Stem Cell Transplantation 1Specimen Handling 1Sirolimus 1Prednisone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Accelerated Phase × blinatumomab × 90 days × Clear all
NCT03263572 2026-05-20

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡